Objective: The objective of the study was to define the clinical, biochemical, and histologic features of liver injury from thiopurines.
A zathioprine (Aza) and 6-mercaptopurine (6-MP) are purine nucleoside analogs (thiopurines) that have potent antiproliferative and immunosuppressive activities and have been in common use for decades. 6-MP was introduced in the 1950s as an antineoplastic agent for the therapy of leukemias and lymphomas. Aza, a prodrug of 6-MP, was introduced in the 1960s, but largely as an immunosuppressive agent, initially for prevention of transplant rejection and later for its corticosteroid-sparing features, as therapy for autoimmune diseases such as inflammatory bowel disease (IBD) and autoimmune hepatitis. Reports on liver injury, sometimes with a fatal outcome, associated with the use of these drugs appeared shortly after their introduction. [1] [2] [3] [4] [5] [6] [7] [8] Since then, >100 cases of liver injury attributed to Aza and 6-MP have been reported (http:// livertox.nlm.nih.gov/Azathioprine.htm). In many cases, the association was confirmed by a prompt recurrence of injury upon readminstration of the agent. [9] [10] [11] [12] [13] In large, prospective 14, 15 and retrospective studies on drug-induced liver injury, Aza and 6-MP are frequently listed as common causes. 16 Indeed, in a recent population-based study from Iceland, Aza was associated with the highest risk for hepatotoxicity, occurring in 1 of 133 persons in whom it was prescribed. 17 Despite the common problem of hepatotoxicity with thiopurines, there is a lack of studies with a significant number of well-characterized patients with this type of liver injury. Most studies have been limited to the IBD patient population and focused largely on asymptomatic elevations of serum aminotransferase levels as the only evidence of liver injury. [18] [19] [20] [21] Clearly, both Aza and 6-MP are associated with transient elevations in serum enzyme levels, but these are usually mild, asymptomatic, and self-limited and may resolve even without dose adjustment or temporary discontinuation. 18 More importantly, both Aza and 6-MP have been implicated in instances of clinically apparent hepatotoxicity, which can be severe, leading to prolonged intrahepatic cholestasis 3, 7 or even acute liver failure. 2, 4, 5 Furthermore, both venoocclusive disease 22 and nodular regenerative hyperplasia (NRH) 23, 24 have been well documented with higher doses and long-term treatment with these agents. Despite the number of case reports and case series, the severity and overall clinical outcomes in patients with liver injury due to Aza and 6-MP have not been well defined. Furthermore, the cross-sensitivity to hepatotoxicity between Aza and 6-MP and possibly to the third thiopurine, 6-thioguanine, has not been fully characterized.
The US Drug-induced Liver Injury Network (DILIN) is a multicenter prospective cohort study that was started in 2004 with the primary aim to enroll patients with liver injury from drugs and dietary supplements to allow for better characterization of the clinical features, pathogenesis, and outcomes of this poorly understood form of liver disease. The current analysis has focused on more fully characterizing the clinical, serologic, and histologic characteristics of patients with liver injury attributed to thiopurines who were enrolled in the DILIN study.
METHODS
The study design of the prospective DILIN study has been described in detail in previous publications. 15, 25 In brief, patients meeting predetermined eligibility criteria were enrolled for structured assessment of potential competing etiologies and a thorough analysis of clinical features and laboratory testing results. Patients were followed up for at least 6 months and, if clinical or laboratory features were still abnormal, were seen again at 12 and 24 months. The causality assessment and the overall diagnosis of druginduced liver injury were based on adjudication by the DILIN Causality Committee using expert consensus. 26 The strength of the relationship between the liver injury and the implicated agent was scored as definite (>95% likelihood), very likely (75% to 94% likelihood), probable (50% to 74% likelihood), possible (25% to 49% likelihood), or unlikely (< 25% likelihood). 19 In addition, the enrolling physician also applied the Rousell-Uclaf Causality Assessment Method to the clinical information that generates a score from À 9 to 14 and is classified as highly probable, [8] [9] [10] [11] [12] [13] probable, 6, 7 (http://livertox.nlm.nih.gov/Azathioprine.htm) possible, [3] [4] [5] unlikely, 1,2 or excluded (r0). 27 Finally, a severity score was assigned as (1) mild, with serum enzyme elevations without jaundice (bilirubin < 2.5 mg/dL) or coagulopathy [International normalized ratio (INR) <1.5], (2) moderate, with bilirubin Z2.5 mg/dL or INRZ1.5, (3) moderate, with bilirubin or INR elevations as above and hospitalized for liver injury, (4) severe, with jaundice and signs of liver failure (such as INRZ1.5, ascites or hepatic encephalopathy), and (5) fatal, with liverrelated death and/or liver transplantation within 6 months of onset of liver injury.
For the current analysis, all patients enrolled between September 2004 and 2014 with liver injury suspected to be due to thioprines were analyzed (Fig. 1 ). Only those cases in which the causality was adjudicated as probable, very likely, or definite were included. The clinical features, laboratory results, and outcomes were obtained from the Duke Clinical Research Institute, the data coordinating center of the DILIN study. All patients were analyzed by 2 of the authors (E.S.B. and J.H.H.) for clinical and laboratory features and outcomes such as progression to chronicity and liver-related death and need for liver transplantation. The type of liver injury was categorized on the basis of the R ratio calculated using the initial values of serum alanine aminotransferase (ALT) divided by alkaline phosphatase (Alk P), both expressed as ratios to upper limits of normal (ULN): R = ALT/ULNAlk P/ULN. By convention, R ratios <2 were defined as cholestatic, 2 to 5 as mixed, and >5 as hepatocellular. 27 The type of liver injury was also assessed using the initial ALT and Alk P values graphed against each other using criteria established by Zimmerman. 28 
Statistical Analysis
Descriptive statistics of demographic and clinical data of Aza cases in comparison with 6-MP cases were generated and analyzed. Description of the data was given as medians (range), frequencies, and percentages. Statistical significance among groups was determined by Wilcoxon ranksum test for continuous variables, Fisher exact test for binary variables, w 2 for categorical variables, and log-rank tests for time-to-event variables. P < 0.05 was considered statistically significant. SAS version 9.4 (SAS Institute, Cary, NC) was used for all statistical analyses.
RESULTS

Clinical Characteristics
Over the initial 10-year period of the prospective DILIN cohort study, 1434 cases of drug-induced liver injury were enrolled and underwent causality assessment, of which 27 were attributed, at least in part, to a thiopurine, including 15 to Aza and12 to 6-MP, but none to 6-thioguanine ( Fig. 1 ). For this analysis, 5 cases were excluded in which liver injury was considered only possibly related to the thiopurine. The remaining 22 cases (12 attributed to Aza and 10 to 6-MP) fulfilled the predefined criteria for inclusion and were used for the current analysis. The demographics and initial clinical features of the 12 Aza and 10 6-MP cases are compared in Table 1 . In most aspects, the clinical features of cases associated with either drug were similar. The 22 cases included 15 women and 7 men, ages 11 to 66 years (mean, 51 y), and all except one (an 11-year-old boy receiving 6-MP for acute lymphocytic leukemia) were adults with an autoimmune condition. Most patients were white (n = 20 including 1 Hispanic white) and 2 were African Americans. The most common indication for therapy was IBD (55%), followed by pulmonary disease of immunologic nature (14%) (sarcoidosis, interstitial lung disease, and idiopathic pulmonary fibrosis), autoimmune hepatitis (9%), systemic lupus erythematosus (9%), and dermatomyositis (9%).
The expert DILIN causality assessment was definite for 2 (9%), very likely for 12 (54%), and probable for 8 (36%) cases, and the distribution was similar for Aza and 6-MP. Rousell-Uclaf Causality Assessment Method scores were also similar with the 2 agents, the median being 6.5 overall with 4 cases rated highly probable, 8, 9 14 probable, 6, 7 (http://livertox.nlm.nih.gov/Azathioprine.htm) and 4 possible. 4 ,5 Viral serologies were negative for hepatitis A, B, C, and E in all patients except for 1 patient with known but stable preexisting chronic hepatitis C. All patients underwent imaging of the liver and biliary tree (ultrasound in 73%, computed tomography in 59%, and magnetic resonance imaging in 27%), and none had evidence of biliary obstruction. Antinuclear antibodies were present in 5 patients (22%) but were thought to be due to the underlying condition (lupus, autoimmune hepatitis in 2, and IBD in 2) in each case. Overall 10 patients (46%) were receiving corticosteroids when they developed liver injury. Only 1 patient was started on treatment with corticosteroids for the liver injury but did not require long-term therapy.
All except 1 patient had symptoms attributable to the liver injury, the most common being jaundice (73%), nausea (64%), fatigue (50%), and abdominal pain (50%). Itching was reported in 6 patients (27%), but was generally transient and mild to moderate in severity. Rash (23%) and fever (27%) were reported in a minority of patients and were not prominent or severe. No patient was diagnosed as having drug reaction with eosinophilia and systemic symptoms syndrome or a severe cutaneous reaction.
The latency to onset, measured as time from starting the medication to identification of laboratory abnormalities, ranged widely from 3 days to almost 10 years, with a median of 75 days. Strikingly, 13 patients (59%) had an escalation of dose before the onset of liver injury, and the median latency from the last dose increase (or initial dose if there were no increase) to onset was 44 days (range, 3 to 254 d). The latency as measured from starting therapy and from the time of the last dose increase is plotted in Figure 2 separately for each case of Aza-induced and 6-MP-induced liver injury. Overall, 59% of cases developed laboratory evidence of DILI within 3 months of starting therapy and 86% within 3 months of the last dose increase. Using either measure, latencies were shorter for Aza than for 6-MP cases, but the differences were of marginal statistical significance. The initial thiopurine dose ranged from 25 to 200 mg (median = 75 mg) daily, the final dose from 50 to 450 mg (median = 150 mg) daily. The median initial and final daily doses were similar in those taking Aza or 6-MP, expressed either as total daily dose or as mg/kg/d (Table 1) . Laboratory results are given in Table 2 , comparing Aza-related and 6-MP-related cases. Serum aminotransferase levels were elevated in all 22 patients, Alk P in 18, and bilirubin (Z2.5 mg/dL) in 16. The initial median (and range) value for ALT was 211 (64 to 625) U/L, that for aspartate aminotransferase was 153 (47 to 603) U/L, for Alk P was 151 (35 to 412) U/L, and for bilirubin was 7.4 (0.6 to 31.8) mg/dL. The median peak values were 13.8 mg/ dL for bilirubin and 1.3 for INR. The R ratio at onset of injury ranged from cholestatic to hepatocellular and the most frequent pattern was in the "mixed hepatitis" range (2 to 5). These R ratios, however, failed to reflect the somewhat unusual relative ratios of ALT to Alk P. In most cases with jaundice, Alk P levels were only modestly elevated and some were within the normal range, at least at the onset of illness. Concurrent ALT levels were generally in the moderate range and never greater than 10-fold elevated. When ALT and Alk P were plotted by absolute value in quadrants using the criteria established by Zimmerman, 28 the values for jaundiced cases were in the range of "canalicular cholestasis" rather than hepatocellular, mixed, or cholestatic hepatitis (Fig. 3) . This pattern is defined by ALT elevations <8 times ULN and Alk P levels <3 times ULN and is most typical of the bland cholestasis that occurs with estrogen-induced or anabolic steroid-induced jaundice. Interestingly, among the 6 anicteric cases, the plotted values of ALT and Alk P were usually in the hepatocellular range and the median R ratio was 8.6 (range, 3 to 22), which was distinctly different from the more cholestatic pattern of the patients who developed jaundice (median R ratio = 2.5; range, 1.1 to 14.2).
The severity of the acute liver injury was scored as mild in 6, moderate in 9, and severe in 7 patients (Table 2 ). 6-MPassociated cases tended to be more severe than the Aza cases both in terms of severity scores (5 of the 7 severe cases were due to 6-MP) as well as initial and peak bilirubin and INR values, but there was considerable overlap. No patient died, but 1 underwent liver transplantation: a 63-year-old man with autoimmune hepatitis and cirrhosis who developed persistent jaundice 2 months after having 6-MP (150 mg daily) added to his corticosteroid therapy, with worsening coagulopathy and hepatic encephalopathy, leading to liver transplantation 41 days later. The histology of the explant revealed postnecrotic cirrhosis, severe cholestasis, and massive necrosis.
All other patients recovered from the acute liver injury clinically, and all except 2 had normal liver tests at a final follow-up assessment. The first of the 2 had preexisting chronic hepatitis C, and aminotransferase levels had been elevated before Aza was started. A second patient had persistent elevations in Alk P that had followed a severe cholestatic hepatitis and a liver biopsy that had shown duct injury and nodular regeneration attributed to 6-MP. At last follow-up, no patient was jaundiced or had symptoms attributable to liver disease. No patient was rechallenged with Aza or 6-MP, but 2 gave a history of a previous episode of liver injury due to Aza: 1 with a recurrence after reexposure to Aza and 1 with recurrence upon treatment with 6-MP.
Liver biopsies were performed during the acute episode in 8 patients, and 7 were available for central review, all among the jaundiced cases. The most common finding was cholestatic hepatitis with lobular and portal inflammation, zone 3 cholestasis and duct injury without duct loss (Figs. 4A, B) . No patient had findings typical of bland cholestasis. One patient had what appeared to be an underlying steatohepatitis and another had a severe autoimmune hepatitis with a superimposed cholestasis. Interestingly, reticulum staining showed that 3 patients had areas of nodular regeneration (Fig. 4C ). All of these 3 patients had severe injury (peak bilirubin >20 mg/dL in all 3 patients) and had been treated for an extended period (73 to 460 d). One had persistent Alk P elevations even after 2 ALT indicates alanine aminotransferase; Alk P, alkaline phosphatase; AST, aspartate aminotransferase. FIGURE 3. Use of the initial ALT and alkaline phosphatase levels and 4 quadrants to characterize the pattern of liver injury as suggested by Zimmerman. 28 The plotting of 12 cases of azathioprine (blue circles) and 10 cases of 6-mercaptopurine liver injury (red circles) for both icteric (closed circles) and anicteric cases (open circles) shows a similar pattern for the 2 drugs, but a different pattern for anicteric cases, which were typically hepatocellular, compared with icteric cases, which were typically cholestatic, but with modest alkaline phosphatase elevations, which is typical of canalicular cholestasis as opposed to hepatocanalicular cholestasis.
years of follow-up and the other 2 resolved the injury both clinically and biochemically.
Thiopurine methyl transferase (TPMT) genotype analysis was available in only 4 patients and was normal in all. Thiopurine (6-methyl mercaptopurine) metabolites were measured at the time of liver injury in 2 Aza-treated patients and were elevated in both, with values of 16,980 and 21,856 pmol/10 8 red blood cells. Stored serum samples were available from many patients, but not from the time of initial onset.
Concise clinical histories of 6 representative patients are provided in the supplementary material (Supplemental Digital Content 1, http://links.lww.com/JCG/A248): 2 had self-limited cholestatic hepatitis, 2 cholestatic hepatitis superimposed upon chronic liver disease, and 2 anicteric hepatitis with hepatocellular enzyme elevations. The clinical courses of other cases are available on the LiverTox website (http://livertox.nlm.nih.gov/Azathioprine.htm).
DISCUSSION
Aza and 6-MP are thiopurines with similar chemical structures and mechanisms of action. Aza acts as a prodrug of 6-MP, differing only by addition of an imido-azo side chain on the 6 0 sulfate. The side chain is removed nonenzymatically in the liver, and Aza tends to be better absorbed and perhaps better tolerated than 6-MP. Nevertheless, the 2 thiopurines have similar activities and side effects.
Both 6-MP and Aza are well-known causes of druginduced liver injury. At least 4 patterns of injury have been associated with their use. First, and most common, is transient and usually asymptomatic elevations in serum enzymes, mostly ALT and AST, which occurs in 5% to 15% of treated subjects. In this series, 6 patients had this pattern of serum aminotransferase elevations accompanied by minor symptoms, but without jaundice. More clinically significant is a second form of hepatotoxicity, an idiosyncratic, cholestatic hepatitis that typically occurs after 1 to 3 months of treatment. Indeed, the majority of cases in the current report had this pattern: 16 patients presenting with jaundice and most with a cholestatic pattern. Both Aza and 6-MP are also capable of causing sinusoidal obstruction syndrome, a third form of hepatotoxicity that occurs when the agents are given in high doses as with cancer chemotherapy. Finally, both agents have also been linked to cases of NRH when given long term, particularly in the setting of organ transplantation or acute leukemia. In this series, 3 of 7 patients who underwent liver biopsy had histologic features of nodular regeneration; however, none subsequently progressed to developed signs or symptoms of portal hypertension. These 4 patterns of injury have also been described with thioguanine. [22] [23] [24] 29 The current analysis showed that Aza-associated and 6-MP-associated liver injury accounted for 1% to 2% of cases of drug-induced liver injury in the DILIN network. Individually, Aza and 6-MP ranked in the top 20 causes of liver injury in the DILIN prospective study and if grouped together would have ranked as the sixth most common cause. 15 In jaundiced cases, the disease was marked by the appearance of fatigue, nausea, vomiting, and abdominal discomfort followed by dark urine and jaundice. Itching was not common and immunoallergic features were rare, and if present generally mild. Strikingly, the latency to onset varied widely and some patients had been receiving thiopurine for years when jaundice arose. In these patients, however, there was usually a history of recent increase in dose. Thus, the latency to onset after starting therapy or after a dose increase was generally a few weeks to 3 months, and rarely exceeded 6 months. Although the course of illness could be severe, it was generally short lived and rapidly improved upon stopping treatment. Only 1 of the 22 patients had evidence of chronic liver injury in long-term follow-up, marked by asymptomatic but persistent elevations in Alk P after a particularly severe bout of cholestatic hepatitis. No patient died with acute liver failure, although 1 patient with a preexisting autoimmune hepatitis and cirrhosis developed an "acute-on-chronic" liver failure and required liver transplantation. Thus, in the absence of preexisting liver disease, the hepatotoxicity of Aza and 6-MP tended to be benign.
In the current study, an intriguing finding was the frequent appearance of liver injury after dose escalation, a pattern that occurred in 59% of patients including 11 of 16 (69%) with jaundice and 2 of 6 (33%) anicteric cases. This finding suggests that the liver injury is partially dose related and that these thiopurines have a degree of intrinsic hepatotoxicity at higher doses. The occurrence of sinusoidal obstruction syndrome and nodular regeneration with the thiopurines further supports their intrinsic hepatotoxicity, at least at higher doses or with longer courses of therapy. Previous experience has shown that elevated liver enzymes during thiopurine therapy can often be managed by reducing the dose with or without a transient period of withdrawal. 18, [30] [31] [32] In contrast, some degree of dose-relatedness has been shown for drugs with well-defined idiosyncratic liver injury, including diclofenac, amoxicillinclavulanic acid, flucloxacillin, and bosentan. [33] [34] [35] Indeed, the majority of drugs that are believed to be hepatotoxic are given in doses of >50 mg daily, suggesting a threshold dose for risk of hepatic injury. [35] [36] [37] Importantly, the finding of a relationship between dose escalation of Aza and MP and the risk for liver injury points to the need of informing patients about the risk for liver injury and monitoring liver tests after increasing the dose. Thus, Aza and 6-MP should be added to a growing list of agents that may have both idiosyncratic and intrinsic hepatotoxic potential.
Another striking feature of the cholestatic hepatitis was the somewhat distinctive pattern of serum enzyme elevations. Thus, despite the disease being cholestatic (verified by liver biopsy), serum Alk P levels were generally low and were normal in many patients at the onset of jaundice. A similar pattern of liver enzyme elevations is typical of anabolic steroid jaundice. 38 However, the clinical course and liver histology of Aza-induced and 6-MPinduced liver injury was distinctly different from that of anabolic steroid injury, which typically causes a prolonged jaundice with severe pruritus and canalicular, bland cholestasis on liver biopsy. The reasons for the minimal Alk P elevations accompanying the cholestatic hepatitis of Aza and 6-MP injury are not clear, but may reflect the activity of these agents in treating liver injury. Both agents are used for immune-mediated forms of hepatitis and therefore might mitigate immune-mediated injury due to the compounds themselves. Another possibility is that the relatively low Alk P levels reflect the effects of concurrent use of corticosteroids (common in the population that receives Aza and 6-MP) or the underlying diseases themselves. Regardless, this pattern may be helpful in identifying Aza or 6-MP as a cause of liver injury in patients on multiple, potentially hepatotoxic agents, or patients with other potential causes of liver injury.
The strength of the current study is the prospective collection of data, well-characterized patients, and good follow-up. The limitations include the lack of patients with NRH related to these drugs because of the entry criteria that are based on liver enzyme elevations. Another limitation as in most other studies on drug-induced liver injury was that the incidence of liver injury among patients taking these drugs could not be estimated. Furthermore, TPMT genotyping was not a part of the study design. Some of these such as NRH related to thiopurines and the TPMT genotyping in this context have been covered in recent reviews. 39 Finally, there is a likelihood of cross-sensitivity to cholestatic liver injury due to these 2 purine analogs. Apart from a recurrence of liver injury in a patient with a previous bout of Aza-induced liver injury, another patient developed prominent hepatotoxicity from 6-MP after an episode of jaundice while taking Aza. Similar cases have been documented in the literature, largely in instances of clinically apparent, icteric liver injury due to these agents.
In conclusion, liver injury from Aza and 6-MP most often occurs within 3 months of exposure or dose escalation, often in women and usually presenting with nonspecific symptoms, followed by jaundice. Generally, 2 patterns of injury can be seen: (1) a transient, mildly symptomatic elevation in serum aminotransferase levels and (2) a cholestatic hepatitis with modest elevations in both ALT and Alk P and moderate to severe jaundice. Although the injury can be severe, the prognosis is generally favorable except in patients with preexisting liver disease. Close monitoring of liver tests may be appropriate after dose escalation of Aza or 6-MP, and the need for treatment in patients with preexisting cirrhosis should be considered carefully before initiating therapy.
